Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2015, Article ID 794592, 4 pages
http://dx.doi.org/10.1155/2015/794592
Case Report

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy

1Division of Pulmonary and Critical Care, Albany Medical Center, Albany, NY, USA
2Division of Pulmonary and Critical Care, National Jewish Health, Denver, CO, USA
3Division of Pulmonary and Critical Care, Cleveland Clinic, Cleveland, OH, USA
4Division of Pulmonary and Critical Care, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Received 28 November 2014; Accepted 14 January 2015

Academic Editor: Kentaro Watanabe

Copyright © 2015 Amit Chopra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. R. Kim, “The burden of hepatitis C in the United States,” Hepatology, vol. 36, no. 5, supplement 1, pp. S30–S34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. W. Fried, “Side effects of therapy of hepatitis C and their management,” Hepatology, vol. 36, no. 5, supplement 1, pp. S237–S244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. K. S. Kumar, M. W. Russo, A. C. Borczuk et al., “Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C,” The American Journal of Gastroenterology, vol. 97, no. 9, pp. 2432–2440, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Ogata, T. Koga, and K. Yagawa, “Interferon-related bronchiolitis obliterans organizing pneumonia,” Chest, vol. 106, no. 2, pp. 612–613, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Crespi, S. Gualandi, F. Piscaglia, and L. Bolondi, “Onset of bronchiolitis obliterans organizing pneumonia in a liver transplant recipient under peg-interferon and ribavirin treatment,” Internal and Emergency Medicine, vol. 3, no. 1, pp. 77–80, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-C. T. Vila, D.-R. P. López, V. B. Company, S. S. Simón, P. C. Hausmann, and J. B. Company, “Organizing pneumonia associated with the use of pegylated interferon α,” Archivos de Bronconeumologia, vol. 44, no. 3, pp. 173–174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. S. Martins, J. A. Machado, and R. Teixeira, “Secondary bronchiolitis obliterans organizing pneumonia during treatment of chronic hepatitis C: role of pegylated interferon α-2a,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 45, no. 5, pp. 655–656, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Gresser, “Biologic effects of interferons,” Journal of Investigative Dermatology, vol. 95, no. 6, supplement, pp. 66–71, 1990. View at Google Scholar · View at Scopus
  10. S. Youngster, Y.-S. Wang, M. Grace, J. Bausch, R. Bordens, and D. F. Wyss, “Structure, biology, and therapeutic implications of pegylated interferon α-2b,” Current Pharmaceutical Design, vol. 8, no. 24, pp. 2139–2157, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. C. Chen, S.-N. Lu, and M.-C. Lin, “Interstitial pneumonitis after combination therapy with pegylated interferon α-2b and ribavirin for chronic hepatitis C,” Chang Gung Medical Journal, vol. 30, no. 1, pp. 92–97, 2007. View at Google Scholar · View at Scopus
  12. J. Midturi, M. Sierra-Hoffman, D. Hurley, R. Winn, R. Beissner, and J. Carpenter, “Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature,” Clinical Infectious Diseases, vol. 39, no. 11, pp. 1724–1729, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. E. C. Borden and D. Parkinson, “A perspective on the clinical effectiveness and tolerance of interferon-α,” Seminars in Oncology, vol. 25, supplement 1, pp. 3–8, 1998. View at Google Scholar · View at Scopus
  14. American Thoracic Society and European Respiratory Society, “American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001,” The American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 2, pp. 277–304, 2002. View at Google Scholar